Tumor cells also underwent significant changes after mANK-101 treatment, including increased expression of proinflammatory chemokines CXCL9 and CXCL10, and upregulation of genes responsible for antigen processing and MHC I presentation, likely mediated by IFN-γ signaling through STAT1. The gene discussed is CXCL9; the disease is neoplasm.